Active substance
Lithium carbonate
- SFDA 1
- US FDA 36
- Health Canada 7
- US price lines 7
- NHS prices 4
- WHO EML 1
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Licarb | 300 mg | Capsule · Oral use | 100 Blister | SAR 100.00 | Generic · Prescription | Saudi Amarox | Valid |
Indications — CHI Daman Drug Formulary
ACUTE MANIA; DEPRESSION
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LITHOBID | 300MG | tablet, extended release · oral | ANI PHARMS | Prescription | 27 Apr 1979 |
| LITHIUM CARBONATE | 300MG; 150MG; 600MG | capsule · oral | HIKMA PHARMS | Prescription | 26 Nov 1980 |
| LITHIUM CARBONATE | 300MG | tablet · oral | HIKMA PHARMS | Prescription | 29 Jan 1982 |
| LITHIUM CARBONATE | 450MG | tablet, extended release · oral | HIKMA PHARMS | Prescription | 5 Jan 2004 |
| LITHIUM CARBONATE | 300MG | tablet, extended release · oral | HIKMA PHARMS | Prescription | 28 Oct 2004 |
| LITHIUM CARBONATE | 150MG; 300MG; 600MG | capsule · oral | ALEMBIC LTD | Prescription | 12 Jan 2009 |
| LITHIUM CARBONATE | 150MG; 300MG; 600MG | capsule · oral | GLENMARK PHARMS LTD | Prescription | 3 Feb 2009 |
| LITHIUM CARBONATE | 150MG; 300MG; 600MG | capsule · oral | HETERO LABS LTD III | Prescription | 25 Sep 2009 |
| LITHIUM CARBONATE | 300MG | tablet, extended release · oral | GLENMARK PHARMS | Prescription | 27 Dec 2010 |
| LITHIUM CARBONATE | 450MG | tablet, extended release · oral | GLENMARK PHARMS LTD | Prescription | 14 Feb 2011 |
| LITHIUM CARBONATE | 300MG | tablet, extended release · oral | UNIQUE | Prescription | 27 Jul 2015 |
| LITHIUM CARBONATE | 300MG | tablet, extended release · oral | HERITAGE PHARMA | Prescription | 29 Sep 2016 |
| LITHIUM CARBONATE | 450MG | tablet, extended release · oral | UNIQUE | Prescription | 5 Jun 2017 |
| LITHONATE | 300MG | capsule · oral | SOLVAY | Discontinued | 6 Apr 1970 |
| LITHIUM CARBONATE | 300MG | tablet · oral | PFIZER | Discontinued | 6 Apr 1970 |
| ESKALITH | 300MG | capsule · oral | NOVEN THERAP | Discontinued | 6 Apr 1970 |
| LITHOTABS | 300MG | tablet · oral | SOLVAY | Discontinued | 24 Apr 1972 |
| ESKALITH | 300MG | tablet · oral | JDS PHARMS | Discontinued | 26 Feb 1979 |
| ESKALITH CR | 450MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, extended release · oral | JDS PHARMS | Discontinued | 29 Mar 1982 |
| LITHANE | 300MG | tablet · oral | BAYER PHARMS | Discontinued | 18 Jul 1985 |
| LITHIUM CARBONATE | 300MG | capsule · oral | ABLE | Discontinued | 27 Sep 2001 |
| LITHIUM CARBONATE | 300MG | tablet, extended release · oral | HERITAGE PHARMA | Discontinued | 10 Jun 2002 |
| LITHIUM CARBONATE | 300MG; 150MG | capsule · oral | PHARMOBEDIENT | Discontinued | 27 Jun 2002 |
| LITHIUM CARBONATE | 300MG | tablet, extended release · oral | ABLE | Discontinued | 21 Apr 2003 |
| LITHIUM CARBONATE | 450MG | tablet, extended release · oral | HIKMA INTL PHARMS | Discontinued | 17 Jun 2003 |
11 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-LITHIUM CARBONATE | 02242837 | 150 MG | CAPSULE · ORAL | APOTEX INC |
| CARBOLITH | 00461733 | 150 MG | CAPSULE · ORAL | BAUSCH HEALTH, CANADA INC. |
| CARBOLITH | 02011239 | 600 MG | CAPSULE · ORAL | BAUSCH HEALTH, CANADA INC. |
| LITHANE | 00406775 | 300 MG | CAPSULE · ORAL | SEARCHLIGHT PHARMA INC |
| LITHANE | 02013231 | 150 MG | CAPSULE · ORAL | SEARCHLIGHT PHARMA INC |
| LITHMAX | 02266695 | 300 MG | TABLET (EXTENDED-RELEASE) · ORAL | AA PHARMA INC |
| PMS-LITHIUM CARBONATE - CAP 150MG | 02216132 | 150 MG | CAPSULE · ORAL | PHARMASCIENCE INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LITHIUM CARBONATE 150 MG CAP | $0.09634 | per EA | 23 Sep 2026 |
| US NADAC | LITHIUM CARBONATE 300 MG CAP | $0.10387 | per EA | 23 Sep 2026 |
| US NADAC | LITHIUM CARBONATE 300 MG TAB | $0.19092 | per EA | 23 Sep 2026 |
| US NADAC | LITHIUM CARBONATE 600 MG CAP | $0.24258 | per EA | 23 Sep 2026 |
| US NADAC | LITHIUM CARBONATE ER 300 MG TB | $0.1963 | per EA | 23 Sep 2026 |
| US NADAC | LITHIUM CARBONATE ER 450 MG TB | $0.25902 | per EA | 23 Sep 2026 |
| US NADAC | LITHOBID ER 300 MG TABLET | $12.01942 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Lithium carbonate 200mg modified-release tablets | £16.42 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lithium carbonate 250mg tablets | £99.53 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lithium carbonate 400mg modified-release tablets | £18.60 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lithium carbonate 450mg modified-release tablets | £11.84 | 60 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 24.2.2. Medicines for bipolar disorders · core
Bipolar or related disorders
Oral > Solid: 300 mg
Safety signals and safety-related labeling changes
- US FDA 13 Oct 2022 LITHIUM CARBONATE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Oct 2022 LITHIUM CARBONATE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Oct 2022 LITHOBID — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.